Insmed (NASDAQ:INSM) Director Elizabeth Anderson Sells 10,000 Shares

Insmed, Inc. (NASDAQ:INSM) Director Elizabeth Anderson sold 10,000 shares of the business’s stock in a transaction on Friday, November 14th. The shares were sold at an average price of $195.87, for a total transaction of $1,958,700.00. Following the completion of the sale, the director directly owned 63,729 shares of the company’s stock, valued at approximately $12,482,599.23. This trade represents a 13.56% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link.

Insmed Stock Performance

Shares of INSM stock opened at $201.62 on Wednesday. The stock’s 50-day moving average is $164.45 and its two-hundred day moving average is $122.82. The company has a debt-to-equity ratio of 0.45, a quick ratio of 6.33 and a current ratio of 6.68. Insmed, Inc. has a 1 year low of $60.40 and a 1 year high of $203.65. The firm has a market cap of $43.00 billion, a price-to-earnings ratio of -35.31 and a beta of 1.05.

Insmed (NASDAQ:INSM) last posted its earnings results on Thursday, October 30th. The biopharmaceutical company reported ($1.75) earnings per share for the quarter, missing the consensus estimate of ($1.35) by ($0.40). The firm had revenue of $142.34 million during the quarter, compared to analysts’ expectations of $114.33 million. Insmed had a negative net margin of 259.82% and a negative return on equity of 195.37%. The firm’s revenue for the quarter was up 52.4% on a year-over-year basis. During the same period in the previous year, the firm posted ($1.27) earnings per share. Insmed has set its FY 2025 guidance at EPS. Analysts predict that Insmed, Inc. will post -4.56 earnings per share for the current year.

Analyst Ratings Changes

Several research firms have recently weighed in on INSM. Mizuho set a $196.00 price objective on Insmed in a report on Wednesday, October 29th. Stifel Nicolaus increased their price target on shares of Insmed from $121.00 to $145.00 and gave the stock a “buy” rating in a research note on Thursday, August 14th. William Blair started coverage on shares of Insmed in a research report on Wednesday, August 20th. They set an “outperform” rating on the stock. Cowen reaffirmed a “buy” rating on shares of Insmed in a report on Thursday, October 30th. Finally, Jefferies Financial Group increased their target price on shares of Insmed from $129.00 to $148.00 and gave the stock a “buy” rating in a research note on Wednesday, August 13th. Nineteen investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $173.29.

Institutional Inflows and Outflows

Several large investors have recently added to or reduced their stakes in the company. Mutual of America Capital Management LLC boosted its holdings in Insmed by 2.7% in the 1st quarter. Mutual of America Capital Management LLC now owns 79,141 shares of the biopharmaceutical company’s stock valued at $6,038,000 after purchasing an additional 2,093 shares in the last quarter. CWM LLC lifted its holdings in shares of Insmed by 24.5% in the 1st quarter. CWM LLC now owns 2,052 shares of the biopharmaceutical company’s stock valued at $157,000 after buying an additional 404 shares during the period. Signaturefd LLC boosted its stake in shares of Insmed by 60.0% in the first quarter. Signaturefd LLC now owns 867 shares of the biopharmaceutical company’s stock valued at $66,000 after buying an additional 325 shares in the last quarter. Cullen Frost Bankers Inc. grew its holdings in Insmed by 164.9% during the first quarter. Cullen Frost Bankers Inc. now owns 355 shares of the biopharmaceutical company’s stock worth $27,000 after acquiring an additional 221 shares during the period. Finally, Teachers Retirement System of The State of Kentucky acquired a new position in Insmed during the first quarter worth $975,000.

About Insmed

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed’s first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.